for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Vericel Corp

VCEL.PH

Latest Trade

48.25USD

Change

0.06(+0.12%)

Volume

3,405

Today's Range

47.21

 - 

48.94

52 Week Range

7.06

 - 

53.79

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
48.19
Open
48.76
Volume
3,405
3M AVG Volume
13.41
Today's High
48.94
Today's Low
47.21
52 Week High
53.79
52 Week Low
7.06
Shares Out (MIL)
45.95
Market Cap (MIL)
2,186.08
Forward P/E
248.67
Dividend (Yield %)
--

Next Event

Vericel Corp Annual Shareholders Meeting

Latest Developments

More

Vericel Reports Fourth Quarter And Full-Year 2020 Financial Results, Provides Full-Year 2021 Financial Guidance

Vericel Corp - Preliminary Total Net Revenues For Q4 2020 Are Expected To Be In Range Of $44.9-$45.4 Mln

Vericel Reports Q3 Earnings Per Share $0.08

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Vericel Corp

Vericel Corporation is an integrated, commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of cellular therapies for use in the treatment of specific diseases.. Its autologous cell therapy products include Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.

Industry

Biotechnology & Drugs

Contact Info

64 Sidney St

CAMBRIDGE, MA

02139-4170

United States

+1.734.9305555

https://vcel.com/

Executive Leadership

Robert L. Zerbe

Independent Chairman of the Board

Dominick C. Colangelo

President, Chief Executive Officer, Director

Joseph A. Mara

Principal Financial Officer, Treasurer

Michael Halpin

Chief Operating Officer

Sandra Pennell

Principal Accounting Officer, Vice President, Controller

Key Stats

1.75 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.1K

2020

0.1K

2021(E)

0.2K
EPS (USD)

2018

-0.200

2019

-0.220

2020

0.060

2021(E)

0.237
Price To Earnings (TTM)
3,028.01
Price To Sales (TTM)
17.60
Price To Book (MRQ)
16.23
Price To Cash Flow (TTM)
409.15
Total Debt To Equity (MRQ)
0.09
LT Debt To Equity (MRQ)
0.06
Return on Investment (TTM)
1.81
Return on Equity (TTM)
1.60

Latest News

Latest News

BRIEF-Vericel - Submission Of Biologics License Application To FDA For Nexobrid

* VERICEL ANNOUNCES SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO THE FDA FOR NEXOBRID FOR THE TREATMENT OF SEVERE THERMAL BURNS

BRIEF-Brown Capital Management Llc Reports 8.34% Passive Stake In Vericel As Of May 31

* BROWN CAPITAL MANAGEMENT LLC REPORTS 8.34% PASSIVE STAKE IN VERICEL AS OF MAY 31 - SEC FILING Source text - https://bit.ly/2Yq61tY Further company coverage:

BRIEF-Vericel Reports First Quarter 2020 Financial Results

* Q1 EARNINGS PER SHARE ESTIMATE $-0.08 -- REFINITIV IBES DATA

BRIEF-Vericel Provides Business And Financial Updates

* VERICEL CORP - FULL YEAR 2020 FINANCIAL GUIDANCE WITHDRAWN DUE TO UNCERTAINTY REGARDING IMPACT OF COVID-19

BRIEF-Vericel Q4 Revenue Rose 41 Pct To $23.4 Mln

* VERICEL REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND PROVIDES FULL YEAR 2018 FINANCIAL GUIDANCE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up